Vivos Therapeutics
VVOS
10 hedge funds and large institutions have $4.32M invested in Vivos Therapeutics in 2020 Q4 according to their latest regulatory filings, with 10 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
0.17% more ownership
Funds ownership: 0% → 0.17% (+0.17%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RA
Royce & Associates
New York
|
+$2.19M |
| 2 |
KJHP
K.J. Harrison & Partners
Toronto,
Ontario, Canada
|
+$667K |
| 3 |
Millennium Management
New York
|
+$609K |
| 4 |
Walleye Capital
New York
|
+$544K |
| 5 |
KPF
K2 Principal Fund
Toronto,
Ontario, Canada
|
+$375K |
Top Sellers
VVOS Hedge Fund Activity: Q4 2020 in Review
10 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in Vivos Therapeutics (VVOS) for Q4 2020, worth a combined $4.32M.
Buyers outnumbered sellers: 10 funds opened new VVOS positions and 0 closed out — a net gain of 10 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Royce & Associates, opening a new position worth an estimated $2.19M.
- 10 institutional investors held Vivos Therapeutics (VVOS) as of Q4 2020, up from 0 in Q3 2020.
- Funds reported $4.32M of Vivos Therapeutics stock for Q4 2020.
- 10 funds opened new Vivos Therapeutics positions in Q4 2020 and 0 closed out, a net change of +10 holders.
- The largest Vivos Therapeutics buyer in Q4 2020 was Royce & Associates, an estimated $2.19M added.
Based on aggregated 13F filings for Q4 2020.